101 Scopus citations


Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The < 100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.

Original languageEnglish (US)
Pages (from-to)563-601
Number of pages39
JournalProgress in Molecular Biology and Translational Science
StatePublished - 2011


  • Cell-based delivery
  • Human immunodeficiency virus
  • Macrophage
  • Mononuclear phagocyte
  • Nanomedicine
  • Nanoparticle
  • Nanotoxicology
  • Neurodegenerative disorders
  • Translational medicine

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine


Dive into the research topics of 'Cell delivery of therapeutic nanoparticles'. Together they form a unique fingerprint.

Cite this